Catalent
CTLT
$55.92
Share price
0.22%
Change (1 day)
27.88%
Change (1 year)
Categories
Catalent is an American pharmaceutical contract research and development company.
Catalent (CTLT) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $6.30 B
According to Catalent's latest financial reports the company's total liabilities are $6.30 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Catalent - Total liabilities on balance sheet (from 2013 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-06-30 | $6.16 B | 7.55% |
| 2022-06-30 | $5.73 B | 18.5% |
| 2021-06-30 | $4.83 B | 13.28% |
| 2020-06-30 | $4.27 B | 9.63% |
| 2019-06-30 | $3.89 B | 13.11% |
| 2018-06-30 | $3.44 B | 26.13% |
| 2017-06-30 | $2.73 B | 11.23% |
| 2016-06-30 | $2.45 B | -1.96% |
| 2015-06-30 | $2.50 B | -27.66% |
| 2014-06-30 | $3.46 B | 3.04% |
| 2013-06-30 | $3.35 B | -3.72% |
| 2012-06-30 | $3.48 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Supernus Pharmaceuticals
SUPN | $0.35 B | -94.35% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | $7.65 B | 21.51% | 🇮🇪 Ireland |
 Aerie Pharmaceuticals AERI | $0.53 B | -91.44% | 🇺🇸 USA |
 Intercept Pharmaceuticals
ICPT | $0.32 B | -94.90% | 🇺🇸 USA |